Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact

Cancer Science

Volumn 106, Issue 6, 2015, Pages 672-686

  Komura, Takuya ^a   Sakai, Yoshio ^a   Harada, Kenichi ^a   Kawaguchi, Kazunori ^a   Takabatake, Hisashi ^a   Kitagawa, Hirohisa ^b   Wada, Takashi ^a   Honda, Masao ^a   Ohta, Tetsuo ^b   Nakanuma, Yasuni ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

CD4+ T cells; Macrophages; Monocytes; Pancreatic ductal adenocarcinoma; Programmed cell death 1

Indexed keywords

CD163 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 7; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 LIGAND 1; CD14 ANTIGEN; CHEMOKINE; CYTOKINE; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HOST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; PANCREAS ADENOCARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPREGULATION; BLOOD; IMMUNOLOGY; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR;

AGED; ANTIGENS, CD14; CARCINOMA, PANCREATIC DUCTAL; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; PANCREATIC NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TRANSCRIPTOME;

EID: 84930418492     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12663     Document Type: Article

References (25)

1. Matsuda T, Ajiki W, Marugame T et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol 2011; 41: 40-51.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-20.
3. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology 2013; 144: 1316-26.
4. Reni M, Cordio S, Milandri C et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6: 369-76.
5. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.
6. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity 2011; 35: 161-8.
7. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319: 47-65.
8. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72: 2162-71.
9. Lesina M, Wörmann SM, Neuhöfer P, Song L, Algül H. Interleukin-6 in inflammatory and malignant diseases of the pancreas. Semin Immunol 2014; 26: 80-7.
10. Sakai Y, Honda M, Fujinaga H et al. Common transcriptional signature of tumor-infiltrating mononuclear inflammatory cells and peripheral blood mononuclear cells in hepatocellular carcinoma patients. Cancer Res 2008; 68: 10267-79.
11. Honda M, Sakai Y, Yamashita T et al. Differential gene expression profiling in blood from patients with digestive system cancers. Biochem Biophys Res Commun 2010; 400: 7-15.
12. Liu W, Putnam AL, Xu-Yu Z et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-11.
13. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-96.
14. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005; 23: 344-6.
15. Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. Immunobiology 2005; 210: 153-60.
16. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37: 129-38.
17. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-95.
18. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013; 14: 1212-8.
19. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492-9.
20. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003; 193: 70-81.
21. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
22. Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996; 4: 329-36.
23. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122: 787-95.
24. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195-204.
25. Akashi K, Kondo M, Weissman IL. Role of interleukin-7 in T-cell development from hematopoietic stem cells. Immunol Rev 1998; 165: 13-28.